
Sign up to save your podcasts
Or
On today's episode of TDR's Trade To Black podcast, we're joined by Payton Nyquvest, Founder and CEO of Numinus Wellness (OTCMKTS: NUMIF), to explore MindMed's groundbreaking announcement from their Phase 2B trial. Take a look into the implications of MindMed's compelling data for anxiety treatments and the broader industry, highlighting the transformative potential of psychedelics in mental health innovation.
5
77 ratings
On today's episode of TDR's Trade To Black podcast, we're joined by Payton Nyquvest, Founder and CEO of Numinus Wellness (OTCMKTS: NUMIF), to explore MindMed's groundbreaking announcement from their Phase 2B trial. Take a look into the implications of MindMed's compelling data for anxiety treatments and the broader industry, highlighting the transformative potential of psychedelics in mental health innovation.
40 Listeners
3,759 Listeners
95 Listeners
1,834 Listeners
204 Listeners
70 Listeners
5,421 Listeners
401 Listeners
104 Listeners
28,563 Listeners
8,604 Listeners
155 Listeners
6 Listeners
11 Listeners
1,165 Listeners